|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung JJ, Lau JY, Goh KL and Leung WK; Asia
Pacific Working Group on Colorectal Cancer. Increasing incidence of
colorectal cancer in Asia: Implications for screening. Lancet
Oncol. 6:871–876. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ullman TA and Itzkowitz SH: Intestinal
inflammation and cancer. Gastroenterology. 140:1807–1816. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waldner MJ, Foersch S and Neurath MF:
Interleukin-6--a key regulator of colorectal cancer development.
Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, de Haar C, Chen M, Deuring J,
Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ:
Disease-related expression of the IL6/STAT3/SOCS3 signalling
pathway in ulcerative colitis and ulcerative colitis-related
carcinogenesis. Gut. 59:227–235. 2010. View Article : Google Scholar
|
|
7
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Semenza GL: HIF-1: Upstream and downstream
of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010.
View Article : Google Scholar :
|
|
11
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ros S and Schulze A: Balancing glycolytic
flux: The role of 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatases in cancer metabolism. Cancer Metab. 1:82013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atsumi T, Chesney J, Metz C, Leng L,
Donnelly S, Makita Z, Mitchell R and Bucala R: High expression of
inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(iPFK-2; PFKFB3) in human cancers. Cancer Res. 62:5881–5887.
2002.PubMed/NCBI
|
|
14
|
Obach M, Navarro-Sabaté A, Caro J, Kong X,
Duran J, Gómez M, Perales JC, Ventura F, Rosa JL and Bartrons R:
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains
hypoxia-inducible factor-1 binding sites necessary for
transactivation in response to hypoxia. J Biol Chem.
279:53562–53570. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neufert C, Becker C and Neurath MF: An
inducible mouse model of colon carcinogenesis for the analysis of
sporadic and inflammation-driven tumor progression. Nat Protoc.
2:1998–2004. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawauchi K, Araki K, Tobiume K and Tanaka
N: p53 regulates glucose metabolism through an IKK-NF-kappaB
pathway and inhibits cell transformation. Nat Cell Biol.
10:611–618. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan L, Han J, Meng Q, Xi Q, Zhuang Q,
Jiang Y, Han Y, Zhang B, Fang J and Wu G: Muscle-specific E3
ubiquitin ligases are involved in muscle atrophy of cancer
cachexia: An in vitro and in vivo study. Oncol Rep. 33:2261–2268.
2015.PubMed/NCBI
|
|
18
|
Grivennikov SI and Karin M: Inflammation
and oncogenesis: A vicious connection. Curr Opin Genet Dev.
20:65–71. 2010. View Article : Google Scholar :
|
|
19
|
Takahashi M, Nakatsugi S, Sugimura T and
Wakabayashi K: Frequent mutations of the beta-catenin gene in mouse
colon tumors induced by azoxymethane. Carcinogenesis. 21:1117–1120.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang QS, Papanikolaou A, Sabourin CL and
Rosenberg DW: Altered expression of cyclin D1 and cyclin-dependent
kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Carcinogenesis. 19:2001–2006. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suzuki R, Kohno H, Sugie S, Nakagama H and
Tanaka T: Strain differences in the susceptibility to azoxymethane
and dextran sodium sulfate-induced colon carcinogenesis in mice.
Carcinogenesis. 27:162–169. 2006. View Article : Google Scholar
|
|
22
|
Becker C, Fantini MC, Schramm C, Lehr HA,
Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al:
TGF-beta suppresses tumor progression in colon cancer by inhibition
of IL-6 trans-signaling. Immunity. 21:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L, et al: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rigby RJ, Simmons JG, Greenhalgh CJ,
Alexander WS and Lund PK: Suppressor of cytokine signaling 3
(SOCS3) limits damage-induced crypt hyper-proliferation and
inflammation-associated tumorigenesis in the colon. Oncogene.
26:4833–4841. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Waldner MJ, Wirtz S, Jefremow A, Warntjen
M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S,
et al: VEGF receptor signaling links inflammation and tumorigenesis
in colitis-associated cancer. J Exp Med. 207:2855–2868. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arvelo F, Sojo F and Cotte C: Biology of
colorectal cancer. E Cancer Medical Sci. 9:5202015.
|
|
28
|
Lahm H, Petral-Malec D, Yilmaz-Ceyhan A,
Fischer JR, Lorenzoni M, Givel JC and Odartchenko N: Growth
stimulation of a human colorectal carcinoma cell line by
interleukin-1 and -6 and antagonistic effects of transforming
growth factor beta 1. Eur J Cancer. 28A:1894–1899. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lang SA, Moser C, Gaumann A, Klein D,
Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, et
al: Targeting heat shock protein 90 in pancreatic cancer impairs
insulin-like growth factor-I receptor signaling, disrupts an
interleukin-6/signal-transducer and activator of transcription
3/hypoxia-inducible factor-1alpha autocrine loop, and reduces
orthotopic tumor growth. Clin Cancer Res. 13:6459–6468. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tanaka T, Narazaki M and Kishimoto T:
Therapeutic targeting of the interleukin-6 receptor. Annu Rev
Pharmacol Toxicol. 52:199–219. 2012. View Article : Google Scholar
|
